Lupin reports 31 percent year on year fall in Q2 net profit

Mumbai: Pharma Major Lupin Limited reported its financial performance for the second quarter ending September 30^th, 2017. These results were taken on record by the Board of Directors at a meeting held in Mumbai.

Key Financial & Performance Highlights

• Sales for the quarter grew by 1.8% to Rs. 38,742 m. compared to Rs. 38,068 m. in Q1 FY2018
  
  
  
  • Sales for quarter decreased by 8.0% compared to Rs. 42,112 m. in Q2 FY2017
  
  
  • H1 FY2018: Sales were Rs. 76,810 m. compared to Rs. 85,530 m. in H1 FY2017
  
  
  
  


• Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) for the quarter grew by 15.8% to Rs. 9,271 m. (23.9% of sales) compared to Rs. 8,003 m. in Q1 FY2018
  
  
  
  • EBITDA for the quarter decreased by 12.3% compared to 10,576 m. in Q2 FY2017
  
  
  • H1 FY 2018: EBITDA was 17,274 m. compared to Rs. 24,510 m. in H1 FY2017
  
  
  
  


• Net profits for the quarter grew by 27.1 % to Rs. 4,550 m. compared to Rs. 3,581 m. in Q1 FY2018
  
  
  
  • Net profits for the quarter decreased by 31.3% compared to Rs. 6,622 m. in Q2 FY2017
  
  
  • H1 FY2018: Net profits were Rs. 8,131 m. compared to Rs. 15,441 m. in H1 FY2017
  
  
  
  


• Investment in Research for the quarter was Rs. 4,739 m., 12.2% of sales

Commenting on the results, Mr. Nilesh Gupta, Managing Director, Lupin Limited, said “In Q2 we have recorded strong growth in all our markets but for the US generic business where we continue to see pricing pressure, as expected. The EBIDTA growth was further fueled by our optimization efforts around operations and R&D investment. We are on track with our complex generic pipeline and have made significant progress on the speciality front with the acquisition of Symbiomix in the US.”